Singapore investing billions more into biomedical R&D

Impatient to see a big payback in new jobs and companies in return for its huge investment in biomedical R&D, Singapore is setting up a $1 billion fund to help promote ties between the science and technology industries. Singapore is preparing to sink another $12 billion into R&D between 2011 and 2015. The city-state is upping the amount of money devoted to achieving economic success from 65 percent of its funds to 70 percent. Story

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.